US · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Iterum Therapeutics PLC ITRMF
9 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
EPS · FY24
$-1.26
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
—
Net margin · FY24
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2024 · full 9-year series below
Revenue
Net income
Per share
USD -1.26
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2024
ROE
Operating margin—
Net margin—
Return on assets-69.9%
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 44.6M
total assets, end of FY2024
Total assetsUSD 44.6M
EquityUSD -4.1M
CashUSD 24.1M
Gross debtUSD 31.2M
Net debtUSD 7.1M
Current ratio1.41×
Net debt stands at -174% of equity.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
EPS, diluted $
−1.26
−2.96
−3.63
−8.41
−32.49
−7.10
−8.82
−170.84
−568.87
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
·
−355.4
−113.6
·
·
−454.5
−138.7
−94.6
−59.4
Shares out B
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
25 of 25
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed